Overall, these results highlight that the RSK–EphA2 axis is under the control of driver oncogenes, and suggest that molecular-targeted agents have the potential to block cancer migration and invasion via inhibition of the RSK–EphA2 pathway. Here, EPHA2 is linked to cancer.